Cargando…
VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models
BACKGROUND: Spinal Muscular Atrophy (SMA) is one of the most common inherited causes of infant death and is caused by the loss of functional survival motor neuron (SMN) protein due to mutations or deletion in the SMN1 gene. One of the treatment strategies for SMA is to induce the expression of the p...
Autores principales: | Hadwen, Jeremiah, MacKenzie, Duncan, Shamim, Fahad, Mongeon, Kevin, Holcik, Martin, MacKenzie, Alex, Farooq, Faraz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895859/ https://www.ncbi.nlm.nih.gov/pubmed/24405637 http://dx.doi.org/10.1186/1750-1172-9-4 |
Ejemplares similares
-
Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway
por: Hadwen, Jeremiah, et al.
Publicado: (2018) -
Current and emerging treatment options for spinal muscular atrophy
por: Farooq, Faraz, et al.
Publicado: (2015) -
Separating the Wheat from the Chaff: The Use of Upstream Regulator Analysis to Identify True Differential Expression of Single Genes within Transcriptomic Datasets
por: Hadwen, Jeremiah, et al.
Publicado: (2021) -
Chitosan-decorated selenium nanoparticles as protein carriers to improve the in vivo half-life of the peptide therapeutic BAY 55-9837 for type 2 diabetes mellitus
por: Rao, Lei, et al.
Publicado: (2014) -
Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
por: Šoltić, Darija, et al.
Publicado: (2020)